Lexaria Bioscience Corp. announced on January 15, 2025, that it has received the necessary independent ethics board approval for human pilot study GLP-1-H25-5. This approval allows its contract research organization to begin implementing and executing the study.
The study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda® (DehydraTECH-liraglutide), to the conventional injected liraglutide (Saxenda®). This marks a significant step in evaluating Lexaria's technology for another major GLP-1 drug.
This regulatory milestone enables Lexaria to advance its clinical pipeline, aiming to demonstrate the potential for an oral alternative to existing injectable liraglutide products.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.